Tempus AI, Verastem to Develop Diagnostic Test for Ovarian Cancer Combination Treatment

MT Newswires Live

05/20

Tempus AI (TEM) said Tuesday it is collaborating with Verastem (VSTM) to develop a companion diagnostic test for a combination treatment for recurrent low-grade serous ovarian cancer.

Tempus said it completed confirmatory testing in Verastem's phase 2 clinical trial, which was the basis of the US Food and Drug Administration's recent accelerated approval of the combination of avutometinib and defactinib.

The company said its xT companion diagnostic assay is being leveraged as an investigational assay to prospectively evaluate KRAS status in patients with recurrent low-grade serous ovarian cancer and categorize patients into KRAS-mutation or KRAS-wild type groups for analysis in the primary and secondary endpoints of Verastem's global phase 3 clinical trial.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2536489776"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2536489776\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2536489776?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-20 21:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2536489776","market":"hk","top_or_hot":-1,"title":"Tempus AI, Verastem to Develop Diagnostic Test for Ovarian Cancer Combination Treatment","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> (TEM) said Tuesday it is collaborating with <a href=\"https://laohu8.com/S/VSTM\">Verastem</a> (VSTM) to develop a companion diagnostic test for a combination treatment for recurrent low-grade serous ovarian cancer.</p><p>Tempus said it completed confirmatory testing in Verastem's phase 2 clinical trial, which was the basis of the US Food and Drug Administration's recent accelerated approval of the combination of avutometinib and defactinib.</p><p>The company said its xT companion diagnostic assay is being leveraged as an investigational assay to prospectively evaluate KRAS status in patients with recurrent low-grade serous ovarian cancer and categorize patients into KRAS-mutation or KRAS-wild type groups for analysis in the primary and secondary endpoints of Verastem's global phase 3 clinical trial.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tempus AI, Verastem to Develop Diagnostic Test for Ovarian Cancer Combination Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTempus AI, Verastem to Develop Diagnostic Test for Ovarian Cancer Combination Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-20 21:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> (TEM) said Tuesday it is collaborating with <a href=\"https://laohu8.com/S/VSTM\">Verastem</a> (VSTM) to develop a companion diagnostic test for a combination treatment for recurrent low-grade serous ovarian cancer.</p><p>Tempus said it completed confirmatory testing in Verastem's phase 2 clinical trial, which was the basis of the US Food and Drug Administration's recent accelerated approval of the combination of avutometinib and defactinib.</p><p>The company said its xT companion diagnostic assay is being leveraged as an investigational assay to prospectively evaluate KRAS status in patients with recurrent low-grade serous ovarian cancer and categorize patients into KRAS-mutation or KRAS-wild type groups for analysis in the primary and secondary endpoints of Verastem's global phase 3 clinical trial.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEM","symbol_name":"Tempus AI","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2536489776","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2536489776","pubTimestamp":1747747567,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Tempus AI  said Tuesday it is collaborating with Verastem  to develop a companion diagnostic test for a combination treatment for recurrent low-grade serous ovarian cancer.Tempus said it completed confirmatory testing in Verastem's phase 2 clinical trial, which was the basis of the US Food and Drug Administration's recent accelerated approval of the combination of avutometinib and defactinib.The company said its xT companion diagnostic assay is being leveraged as an investigational assay to prospectively evaluate KRAS status in patients with recurrent low-grade serous ovarian cancer and categorize patients into KRAS-mutation or KRAS-wild type groups for analysis in the primary and secondary endpoints of Verastem's global phase 3 clinical trial.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEM":"Tempus AI","BK7095":"多种金属与采矿","BK4139":"生物科技","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU1861558580.USD":"日兴方舟颠覆性创新基金B","TEM.AU":"TEMPEST MINERALS LTD","BK4613":"AI应用软件","BK4611":"AI医疗","BK4121":"生命科学工具和服务","VSTM":"Verastem"},"translate_title":"Tempus AI与Verastem合作开发卵巢癌联合治疗诊断测试","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":1,"TEM.AU":1,"VSTM":1},"content_text":"Tempus AI (TEM) said Tuesday it is collaborating with Verastem (VSTM) to develop a companion diagnostic test for a combination treatment for recurrent low-grade serous ovarian cancer.Tempus said it completed confirmatory testing in Verastem's phase 2 clinical trial, which was the basis of the US Food and Drug Administration's recent accelerated approval of the combination of avutometinib and defactinib.The company said its xT companion diagnostic assay is being leveraged as an investigational assay to prospectively evaluate KRAS status in patients with recurrent low-grade serous ovarian cancer and categorize patients into KRAS-mutation or KRAS-wild type groups for analysis in the primary and secondary endpoints of Verastem's global phase 3 clinical trial.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}